Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
David Charles Montefiori
Professor in Surgery
Surgery, Surgical Sciences
monte@duke.edu
Box 2926 Med Ctr, Durham, NC
Surgical Oncology Res Fac, Durham, NC 27710
Research
More About This Person
glance {hide_children: true, active: false, enabled: true}
At a Glance
credentials {hide_children: true, active: false, enabled: true}
Credentials
Education
academic-experience {hide_children: true, active: false, enabled: true}
Academic Experience
Current Appointments & Affiliations
Previous Appointments & Affiliations
expertise {hide_children: true, active: false, enabled: false}
Expertise
research {hide_children: false, active: true, enabled: true}
Research
Selected Grants
publications {hide_children: true, active: false, enabled: true}
Publications
Selected Publications
artistic-works {hide_children: true, active: false, enabled: false}
Artistic Works / Events
teaching {hide_children: true, active: false, enabled: false}
Teaching
advising-mentoring {hide_children: true, active: false, enabled: false}
Advising & Mentoring
recognition {hide_children: true, active: false, enabled: true}
Recognition
In the News
professional-activities {hide_children: true, active: false, enabled: false}
Professional Activities
Manage Profile
Embed Profile Data
Manage Profile
Embed Profile Data
Selected Grants
Nonhuman Primate Core-Option 6
Research
Co Investigator ·
Awarded by National Institutes of Health ·
2025 - 2032
Neutralizing Antibody Assessment to Support bnAb Production
Research
Principal Investigator ·
Awarded by Advanced Bioscience Laboratories, Inc. ·
2024 - 2028
CAVIMC 2022-2026 Grant Renewal
Research
Principal Investigator ·
Awarded by Bill and Melinda Gates Foundation ·
2016 - 2027
HVTN Lab Center: B Cell Supplement
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Center ·
2023 - 2027
HVTN Laboratory Center: Phase 1 PF
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Center ·
2022 - 2027
HIV Vaccine Trials Network Laboratory Center
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Center ·
2022 - 2027
ABL PGDM14 BIJ93.LS Stability Testing Program (Opt 1)
Research
Principal Investigator ·
Awarded by Advanced Bioscience Laboratories, Inc. ·
2024 - 2027
Neutralizing antibody assessment for Subprotocol 03 to Master Protocol mRNA-1273-P403
Research
Principal Investigator ·
Awarded by Moderna Therapeutics, Inc. ·
2025 - 2027
Neutralizing antibody assessment for Subprotocol 01 to Master Protocol mRNA-1283-P401
Research
Principal Investigator ·
Awarded by Moderna Therapeutics, Inc. ·
2025 - 2026
Moderna mRNA 1273 P403-M (SARS Cov 2) Vaccine Trial Neutralizing Antibody Assessment and SARS-CoV-2 Variant Characterization and Validation
Research
Principal Investigator ·
Awarded by Moderna Therapeutics, Inc. ·
2024 - 2026
CISA 2023-03 Task 4 Lead - COVID immunogenicity
Research
Investigator ·
Awarded by Centers for Disease Control and Prevention ·
2023 - 2026
CIVICS A - Option 21A Equitable Adjustment
Research
Principal Investigator ·
Awarded by National Institutes of Health ·
2022 - 2026
CIVICS A - Option 21A
Research
Principal Investigator ·
Awarded by National Institute of Allergy and Infectious Diseases ·
2021 - 2026
Neutralizing Antibody Assessment for UVAX-HIV-101 Human Clinical Trial Study
Research
Co Investigator ·
Awarded by Uvax Bio, LLC ·
2024 - 2026
Neutralizing Antibody Assessment for Grifols Anti-SARS-CoV-2 IgG and Human Plasma Samples
Research
Principal Investigator ·
Awarded by Grifols Worldwide Operations ·
2025 - 2026
Moderna mRNA1273 P403-M study Sub-protocol 2: A Phase 3b/4, Open-label Study to Assess the Immunogenicity of mRNA-1273.172 in Previously Vaccinated Adults Aged ¿18 years
Research
Principal Investigator ·
Awarded by Moderna Therapeutics, Inc. ·
2024 - 2025
CIVICs A - Option 18C
Research
Principal Investigator ·
Awarded by National Institutes of Health ·
2022 - 2025
Neutralizing Antibody Assessment for SARS-CoV-2 Vaccine Trials
Research
Principal Investigator ·
Awarded by Vaccine Company, Inc. ·
2023 - 2025
Moderma COVID/Flu 1083-P301
Research
Principal Investigator ·
Awarded by Moderna Therapeutics, Inc. ·
2024 - 2025
Nonhuman Primate Option 6
Research
Co Investigator ·
Awarded by National Institutes of Health ·
2018 - 2025
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses - Option 5
Research
Investigator ·
Awarded by National Institutes of Health ·
2023 - 2024
CoVPN 5001 A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Center ·
2022 - 2024
CISA COVID Flu Immunogenicity
Research
Investigator ·
Awarded by Centers for Disease Control and Prevention ·
2022 - 2024
CISA COVID Peds Immunogenicity
Research
Investigator ·
Awarded by Centers for Disease Control and Prevention ·
2022 - 2024
CISA Maternal COVID Immunogenicity
Research
Investigator ·
Awarded by Centers for Disease Control and Prevention ·
2022 - 2024
EQAPOL SARS CoV-2 Option 46
Research
Co-Principal Investigator ·
Awarded by National Institutes of Health ·
2022 - 2024
Duke CTSA (TL1) Year 5
Inst. Training Prgm or CME
Mentor ·
Awarded by National Institutes of Health ·
2018 - 2024
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years
Research
Principal Investigator ·
Awarded by Moderna Therapeutics, Inc. ·
2021 - 2024
Moderna mRNA1275 P205 Trial Neutralizing Antibody Assessment
Research
Principal Investigator ·
Awarded by Moderna Therapeutics, Inc. ·
2021 - 2024
HVTN Supplement 2022
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Center ·
2022 - 2023
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Center ·
2022 - 2023
CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Center ·
2022 - 2023
A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled, Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effe
Research
Principal Investigator ·
Awarded by Moderna Therapeutics, Inc. ·
2021 - 2023
Moderna mRNA-1273 P201 (Part B) Trial Neutralizing Antibody Assessment
Research
Principal Investigator ·
Awarded by Moderna Therapeutics, Inc. ·
2021 - 2023
CIVICs A - Option 18B SAVE Aim 3
Research
Investigator ·
Awarded by National Institute of Allergy and Infectious Diseases ·
2021 - 2023
A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls
Research
Principal Investigator ·
Awarded by Moderna Therapeutics, Inc. ·
2021 - 2023
Neutralizing Antibody Response Assessment for a Phase 2/3 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccin
Research
Principal Investigator ·
Awarded by Moderna Therapeutics, Inc. ·
2021 - 2023
EQAPOL SARS CoV-2 Option 44
Research
Co-Principal Investigator ·
Awarded by National Institutes of Health ·
2021 - 2022
A PHASE 2a, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1273 SARS-COV-2 VACCINE IN ADULTS AGED 18 YEARS A
Research
Principal Investigator ·
Awarded by Moderna Therapeutics, Inc. ·
2021 - 2022
Neutralizing antibody assessment for EID 030 SARS-CoV-2 Vaccine Phase I trial
Research
Principal Investigator ·
Awarded by Henry M. Jackson Foundation ·
2021 - 2022
CIVICs A - Option 18A SAVE Aims 1, 2
Research
Principal Investigator ·
Awarded by National Institute of Allergy and Infectious Diseases ·
2021 - 2022
HVTN Laboratory Center: Phase 1 PF
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Research Center ·
2020 - 2022
CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Research Center ·
2020 - 2022
CoVPN 5001 A prospective study of acute immune responses to SARS-CoV2 infection - LAB
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Research Center ·
2020 - 2022
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Research Center ·
2020 - 2022
EQAPOL SARS CoV-2 EQA Option 43
Research
Co-Principal Investigator ·
Awarded by National Institutes of Health ·
2021 - 2021
EQAPOL SARS CoV-2 EQA Option 42
Research
Co-Principal Investigator ·
Awarded by National Institutes of Health ·
2020 - 2021
Role of neutralizing antibodies in HIV-1-infected and vaccinated mothers in MTCT
Research
Collaborator ·
Awarded by National Institutes of Health ·
2016 - 2021
Primate Contract Expansion for Covid-19
Research
Investigator ·
Awarded by National Institutes of Health ·
2020 - 2021
Protocol Development Assays
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Research Center ·
2019 - 2020
HVTN Laboratory Center: HVTN 704
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Research Center ·
2015 - 2020
HVTN Laboratory Center: HVTN Phase 1
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Research Center ·
2015 - 2020
HVTN Laboratory Center: HVTN 117
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Research Center ·
2017 - 2018
HVTN Laboratory Center: HVTN 118
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Research Center ·
2017 - 2018
RAMP Scholar Award Shay Behrens
Research
Principal Investigator ·
Awarded by Fred Hutchinson Cancer Research Center ·
2016 - 2018
HIV Vaccine Trials Network: LC P5 PF
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Research Center ·
2015 - 2018
Nonhuman Primate Core-Option 6
Research
Principal Investigator ·
Awarded by National Institutes of Health ·
2012 - 2018
Option 13 Non Human Primate Core
Research
Principal Investigator ·
Awarded by National Institutes of Health ·
2012 - 2018
Option 19 Non Human Primate Core
Research
Principal Investigator ·
Awarded by National Institutes of Health ·
2012 - 2017
LC: HIV Vaccine Trials Network: Phase 1 PF
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Research Center ·
2014 - 2015
HIV Vaccine Trials Network: LC P5 PF
Research
Co Investigator ·
Awarded by Fred Hutchinson Cancer Research Center ·
2014 - 2015
HIV Envelope-specific functional antibody responses in HIV-exposed, HIV-vaccinated infants
Research
Collaborator ·
Awarded by National Institutes of Health ·
2012 - 2015
Methods to Determine HIV Transport and Inactivation by Microbicide Coating Layers
Research
Significant Contributor ·
Awarded by National Institutes of Health ·
2009 - 2012
Nonhuman Primate Core Humoral Immunology Laboratory for AIDS Vaccine Research and Development
Research
Principal Investigator ·
Awarded by National Institutes of Health ·
2011 - 2012
Central Laboratory for the HIV Vaccines Trial Network
Research
Co Investigator ·
Awarded by National Institutes of Health ·
2000 - 2006
A Universal Env Immunogen for all HIV-1 Subtypes
Research
Consultant ·
Awarded by National Institutes of Health ·
2003 - 2006
Same
Research
Administrative Assistant ·
Awarded by National Institutes of Health ·
1997 - 2002
Host Virus Interactions During Acute Infection
Research
Co-Principal Investigator ·
Awarded by National Institutes of Health ·
1996 - 1999
Perform Neutralizing Assays On Hiv,Siv,And Shiv, And Adopt
Research
Principal Investigator ·
Awarded by National Institutes of Health ·
1993 - 1998
